We recently published a list of 10 Best Immunology Stocks To Buy Now. In this article, we are going to take a look at where ...

Sanofi and CD&R have signed a share purchase agreement for the sale of a 50% stake in the consumer health business.

Following similar deals in countries like the United States and the U.K., Canada is bolstering its stockpile of bird flu ...

according to Sanofi. It has also been approved to date in the EU, GB, and Canada. New data from the phase 3b, real-world HARMONIE study has confirmed the efficacy of Beyfortus in clinical trials ...

Turning back to Canada, Ryan Bushell ... 32 Headquartered in Paris, France, Sanofi (NASDAQ:SNY) is a global healthcare company providing therapeutic solutions for diabetes, cardiovascular diseases ...

The company has struggled to keep up with the pace of its rivals Moderna and Pfizer, which make messenger RNA-based vaccines ...

Zacks Research cut their Q2 2025 EPS estimates for shares of Sanofi in a research report issued on Wednesday, February 19th.

Sanofi has moved ahead with plans to challenge ... MSD (known as Merck & Co in the US and Canada), meanwhile, recorded $647 million with its rival conjugate vaccine Vaxneuvance and another $ ...

Sanofi could be "bit more" active with M&A in near future, CFO says Sanofi's R&D spending to see limited increase in 2025 Beyfortus sales double, Dupixent sales miss estimates Jan 30 - Sanofi ...

Sanofi has bought back a €3bn ($3.1bn) stake held by cosmetics giant L'Oréal, the first of multiple share buybacks the French drugmaker has planned for 2025. L'Oréal was selling 29,556,650 ...